 Kevin Ginn
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 5 | 2021 | 27 | 1.410 |
Why?
| | Medulloblastoma | 2 | 2019 | 32 | 0.820 |
Why?
| | ral GTP-Binding Proteins | 1 | 2016 | 1 | 0.650 |
Why?
| | Cerebellum | 1 | 2016 | 15 | 0.640 |
Why?
| | Craniopharyngioma | 2 | 2020 | 2 | 0.430 |
Why?
| | Mutation | 3 | 2020 | 202 | 0.270 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2021 | 1 | 0.230 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 3 | 0.230 |
Why?
| | Spinal Cord Neoplasms | 1 | 2021 | 3 | 0.230 |
Why?
| | Humans | 9 | 2021 | 5964 | 0.220 |
Why?
| | Tissue Array Analysis | 1 | 2020 | 3 | 0.220 |
Why?
| | Male | 6 | 2021 | 3237 | 0.220 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 3 | 0.220 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 8 | 0.210 |
Why?
| | Pituitary Neoplasms | 1 | 2020 | 1 | 0.210 |
Why?
| | Transcriptome | 1 | 2020 | 34 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 83 | 0.200 |
Why?
| | Skin Abnormalities | 1 | 2019 | 2 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 117 | 0.200 |
Why?
| | Syndactyly | 1 | 2019 | 4 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 84 | 0.200 |
Why?
| | Craniofacial Abnormalities | 1 | 2019 | 10 | 0.200 |
Why?
| | Intestines | 1 | 2019 | 27 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 205 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 145 | 0.180 |
Why?
| | Female | 4 | 2021 | 3320 | 0.170 |
Why?
| | Transduction, Genetic | 1 | 2016 | 3 | 0.160 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2016 | 3 | 0.160 |
Why?
| | Aurora Kinase A | 1 | 2016 | 3 | 0.160 |
Why?
| | Mice, Nude | 1 | 2016 | 16 | 0.160 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 23 | 0.160 |
Why?
| | Gene Silencing | 1 | 2016 | 11 | 0.160 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 15 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 31 | 0.160 |
Why?
| | Fetus | 1 | 2016 | 24 | 0.160 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 66 | 0.160 |
Why?
| | Cell Proliferation | 1 | 2016 | 68 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 99 | 0.160 |
Why?
| | Infant, Newborn | 4 | 2021 | 877 | 0.150 |
Why?
| | Signal Transduction | 1 | 2016 | 150 | 0.150 |
Why?
| | Protoporphyria, Erythropoietic | 1 | 2015 | 1 | 0.150 |
Why?
| | Chromosomes, Human, X | 1 | 2015 | 3 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 5 | 0.150 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2015 | 4 | 0.150 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2015 | 1 | 0.150 |
Why?
| | Carcinoma | 1 | 2015 | 3 | 0.150 |
Why?
| | Mice | 1 | 2016 | 441 | 0.140 |
Why?
| | Primary Health Care | 1 | 2014 | 42 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 61 | 0.140 |
Why?
| | Animals | 1 | 2016 | 884 | 0.130 |
Why?
| | Neoplasms | 1 | 2014 | 90 | 0.130 |
Why?
| | Child | 4 | 2021 | 2796 | 0.110 |
Why?
| | Algorithms | 2 | 2020 | 96 | 0.100 |
Why?
| | Infant | 3 | 2020 | 1371 | 0.100 |
Why?
| | Young Adult | 2 | 2021 | 582 | 0.090 |
Why?
| | Child, Preschool | 3 | 2020 | 1442 | 0.090 |
Why?
| | Adult | 2 | 2021 | 1082 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 6 | 0.060 |
Why?
| | Data Accuracy | 1 | 2020 | 6 | 0.050 |
Why?
| | Preoperative Period | 1 | 2020 | 5 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2020 | 6 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 26 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 33 | 0.050 |
Why?
| | Computational Biology | 1 | 2020 | 27 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 142 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 101 | 0.050 |
Why?
| | Cohort Studies | 1 | 2020 | 256 | 0.050 |
Why?
| | Middle Aged | 1 | 2020 | 551 | 0.040 |
Why?
| | 5-Aminolevulinate Synthetase | 1 | 2015 | 1 | 0.040 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 4 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2015 | 5 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 14 | 0.040 |
Why?
| | Genetic Linkage | 1 | 2015 | 6 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 18 | 0.040 |
Why?
| | International Agencies | 1 | 2015 | 1 | 0.040 |
Why?
| | Carboplatin | 1 | 2015 | 1 | 0.040 |
Why?
| | Cranial Irradiation | 1 | 2015 | 1 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 1 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2015 | 6 | 0.040 |
Why?
| | Cisplatin | 1 | 2015 | 6 | 0.040 |
Why?
| | Vincristine | 1 | 2015 | 6 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2015 | 14 | 0.040 |
Why?
| | Etoposide | 1 | 2015 | 11 | 0.040 |
Why?
| | Biopsy | 1 | 2015 | 55 | 0.040 |
Why?
| | Survival Rate | 1 | 2015 | 79 | 0.040 |
Why?
| | Emergencies | 1 | 2014 | 11 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 74 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 44 | 0.030 |
Why?
| | Prognosis | 1 | 2015 | 179 | 0.030 |
Why?
| | Adolescent | 1 | 2020 | 1931 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2015 | 307 | 0.030 |
Why?
| | Liver | 1 | 2015 | 159 | 0.030 |
Why?
| | Risk Factors | 1 | 2014 | 389 | 0.030 |
Why?
| | Prospective Studies | 1 | 2015 | 460 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|